Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Hebelstrasse 10, CH-4031 Basel, Switzerland.
BMJ. 2013 Oct 22;347:f5934. doi: 10.1136/bmj.f5934.
To quantify the overall effects of bariatric surgery compared with non-surgical treatment for obesity.
Systematic review and meta-analysis based on a random effects model.
Searches of Medline, Embase, and the Cochrane Library from their inception to December 2012 regardless of language or publication status.
Eligible studies were randomised controlled trials with ≥ 6 months of follow-up that included individuals with a body mass index ≥ 30, compared current bariatric surgery techniques with non-surgical treatment, and reported on body weight, cardiovascular risk factors, quality of life, or adverse events.
The meta-analysis included 11 studies with 796 individuals (range of mean body mass index at baseline 30-52). Individuals allocated to bariatric surgery lost more body weight (mean difference -26 kg (95% confidence interval -31 to -21)) compared with non-surgical treatment, had a higher remission rate of type 2 diabetes (relative risk 22.1 (3.2 to 154.3) in a complete case analysis; 5.3 (1.8 to 15.8) in a conservative analysis assuming diabetes remission in all non-surgically treated individuals with missing data) and metabolic syndrome (relative risk 2.4 (1.6 to 3.6) in complete case analysis; 1.5 (0.9 to 2.3) in conservative analysis), greater improvements in quality of life and reductions in medicine use (no pooled data). Plasma triglyceride concentrations decreased more (mean difference -0.7 mmol/L (-1.0 to -0.4) and high density lipoprotein cholesterol concentrations increased more (mean difference 0.21 mmol/L (0.1 to 0.3)). Changes in blood pressure and total or low density lipoprotein cholesterol concentrations were not significantly different. There were no cardiovascular events or deaths reported after bariatric surgery. The most common adverse events after bariatric surgery were iron deficiency anaemia (15% of individuals undergoing malabsorptive bariatric surgery) and reoperations (8%).
Compared with non-surgical treatment of obesity, bariatric surgery leads to greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome. However, results are limited to two years of follow-up and based on a small number of studies and individuals.
PROSPERO CRD42012003317 (www.crd.york.ac.uk/PROSPERO).
定量评估减重手术与非手术治疗肥胖的总体效果。
基于随机效应模型的系统评价和荟萃分析。
从各数据库的起始时间至 2012 年 12 月检索 Medline、Embase 和 Cochrane Library,不考虑语言或出版状态。
纳入研究为至少 6 个月随访的随机对照试验,纳入对象的体质指数(BMI)≥30,比较了当前的减重手术技术与非手术治疗,并报告了体重、心血管危险因素、生活质量或不良事件。
荟萃分析纳入了 11 项研究共 796 例患者(基线时 BMI 范围为 30-52)。与非手术治疗相比,接受减重手术的患者体重减轻更多(平均差值-26kg[95%置信区间-31 至-21]),2 型糖尿病缓解率更高(完全分析中相对风险 22.1[3.2 至 154.3];保守分析中假定所有失访的非手术治疗患者糖尿病缓解,相对风险 5.3[1.8 至 15.8]),代谢综合征缓解率更高(完全分析中相对风险 2.4[1.6 至 3.6];保守分析中相对风险 1.5[0.9 至 2.3]),生活质量改善更大,药物使用减少(无汇总数据)。血浆甘油三酯浓度降低更多(平均差值-0.7mmol/L[-1.0 至-0.4]),高密度脂蛋白胆固醇浓度升高更多(平均差值 0.21mmol/L[0.1 至 0.3])。血压和总胆固醇或低密度脂蛋白胆固醇浓度的变化无显著差异。减重手术后未报告心血管事件或死亡。减重手术后最常见的不良事件是缺铁性贫血(吸收不良性减重手术患者的 15%)和再手术(8%)。
与肥胖的非手术治疗相比,减重手术可导致更大程度的体重减轻,以及更高的 2 型糖尿病和代谢综合征缓解率。然而,结果仅限于两年的随访期,且基于少数研究和患者。
PROSPERO CRD42012003317(www.crd.york.ac.uk/PROSPERO)。